Cargando…
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
The current prevalence of infections caused by multidrug-resistant (MDR) organisms is a global threat, and thus, the development of new antimicrobial agents with activity against these pathogens is a healthcare priority. Ceftolozane–tazobactam (C/T) is a new combination of a cephalosporin with a β-l...
Autores principales: | Escolà-Vergé, Laura, Pigrau, Carlos, Almirante, Benito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613001/ https://www.ncbi.nlm.nih.gov/pubmed/31308706 http://dx.doi.org/10.2147/IDR.S180905 |
Ejemplares similares
-
Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016) -
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
por: Popejoy, Myra W., et al.
Publicado: (2017) -
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016) -
Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
por: Skalweit, Marion J
Publicado: (2015) -
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections
por: Saeed, Muhammad Waqas, et al.
Publicado: (2022)